drugset / Trial / NCT03175354
A Study in Subjects With Moderate Atopic Dermatitis
RandomizedParallel-groupTriple-blindTreatment
Summary
This is a randomized, double-blind, vehicle-controlled study to evaluate the safety and efficacy of ALX-101 Gel 1.5% and 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 42 days to adult and adolescent subjects with moderate atopic dermatitis.
Timeline
- Start
- 2017-04-26
- Primary completion
- 2018-06-29
- Completion
- 2018-06-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ROVAZOLAC | Small molecule | 1.5 % | Topical |
| Subject | ROVAZOLAC | Small molecule | 5 % | Topical |